治疗方案-话题@MedSci

#治疗方案#

313篇内容 | 3067人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1905187, encodeId=a5e2190518e94, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=Lancet Oncol：CDKI联合氟维司群有望成为激素受体阳性、HER2阴性的晚期乳腺癌的标准治疗方案！, objectType=article, longId=219161, objectId=aee8219161b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aee8219161b7, replyNumber=0, likeNumber=89, createdTime=2022-09-06, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aee8219161b7, moduleTitle=Lancet Oncol：CDKI联合氟维司群有望成为激素受体阳性、HER2阴性的晚期乳腺癌的标准治疗方案！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aee8219161b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905152, encodeId=5338190515204, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle= J Clin Oncol：卡铂/依托泊苷方案+阿妥珠单抗作为广泛期小细胞肺癌一线治疗方案的延长随访预后结果（IMpower133试验）, objectType=article, longId=205905, objectId=050d20590572, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=050d20590572, replyNumber=0, likeNumber=0, createdTime=2021-06-14, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=050d20590572, moduleTitle= J Clin Oncol：卡铂/依托泊苷方案+阿妥珠单抗作为广泛期小细胞肺癌一线治疗方案的延长随访预后结果（IMpower133试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=050d20590572)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905164, encodeId=917b1905164bc, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=NEJM：利福喷丁-莫西沙星4个月治疗方案用于结核病的治疗, objectType=article, longId=210906, objectId=74d8210906a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74d8210906a2, replyNumber=0, likeNumber=86, createdTime=2021-08-16, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74d8210906a2, moduleTitle=NEJM：利福喷丁-莫西沙星4个月治疗方案用于结核病的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74d8210906a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905150, encodeId=f8611905150fb, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=骨髓瘤治疗新进展，全新作用机制药物Selinexor（ATG-010）三种治疗方案入选更新版NCCN®多发性骨髓瘤诊疗指南, objectType=article, longId=204590, objectId=39b1204590b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39b1204590b5, replyNumber=0, likeNumber=83, createdTime=2021-04-16, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39b1204590b5, moduleTitle=骨髓瘤治疗新进展，全新作用机制药物Selinexor（ATG-010）三种治疗方案入选更新版NCCN®多发性骨髓瘤诊疗指南, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39b1204590b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905153, encodeId=c4561905153e2, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=【瞩目】铂敏感复发性卵巢癌：卡铂-多柔比星-贝伐珠单抗或许是新的标准治疗方案, objectType=article, longId=206078, objectId=28d22060e857, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28d22060e857, replyNumber=0, likeNumber=65, createdTime=2021-11-12, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28d22060e857, moduleTitle=【瞩目】铂敏感复发性卵巢癌：卡铂-多柔比星-贝伐珠单抗或许是新的标准治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28d22060e857)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905171, encodeId=4d9619051e106, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=J Clin Oncol：两种治疗方案对晚期霍奇金淋巴瘤年轻患者性腺功能的影响PK！, objectType=article, longId=213187, objectId=d9b921318e2b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9b921318e2b, replyNumber=0, likeNumber=97, createdTime=2022-01-08, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9b921318e2b, moduleTitle=J Clin Oncol：两种治疗方案对晚期霍奇金淋巴瘤年轻患者性腺功能的影响PK！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9b921318e2b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905156, encodeId=04ae1905156c8, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=Medicine：乌司他丁联合中药大黄可能是改善败血症的一种有前景的治疗方案, objectType=article, longId=207769, objectId=9acb20e769a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9acb20e769a1, replyNumber=0, likeNumber=73, createdTime=2021-05-21, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9acb20e769a1, moduleTitle=Medicine：乌司他丁联合中药大黄可能是改善败血症的一种有前景的治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9acb20e769a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905168, encodeId=f0dd190516822, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=JCO：两种辅助治疗方案用于I期HER2+乳腺癌患者的疗效对比, objectType=article, longId=212324, objectId=1b0521232415, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b0521232415, replyNumber=0, likeNumber=84, createdTime=2022-02-25, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b0521232415, moduleTitle=JCO：两种辅助治疗方案用于I期HER2+乳腺癌患者的疗效对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b0521232415)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905166, encodeId=73041905166b7, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=Lancet Oncol：3期| 派姆单抗和化疗联用或单用作为晚期尿路上皮癌的一线治疗方案的疗效对比！, objectType=article, longId=211950, objectId=274d2119505a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=274d2119505a, replyNumber=0, likeNumber=51, createdTime=2022-03-18, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=274d2119505a, moduleTitle=Lancet Oncol：3期| 派姆单抗和化疗联用或单用作为晚期尿路上皮癌的一线治疗方案的疗效对比！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=274d2119505a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905169, encodeId=8bea1905169c9, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=Ann Hematol：ixazomib口服治疗方案有望成为NDMM患者的良好替代治疗选择, objectType=article, longId=212449, objectId=882221244968, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=882221244968, replyNumber=0, likeNumber=57, createdTime=2021-08-29, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=882221244968, moduleTitle=Ann Hematol：ixazomib口服治疗方案有望成为NDMM患者的良好替代治疗选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=882221244968)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905158, encodeId=cf89190515891, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=HIV研究瞄准合并症风险，常规治疗方案难逃血脂问题, objectType=article, longId=208851, objectId=77a42088517e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77a42088517e, replyNumber=0, likeNumber=59, createdTime=2021-12-06, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77a42088517e, moduleTitle=HIV研究瞄准合并症风险，常规治疗方案难逃血脂问题, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77a42088517e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905160, encodeId=2e65190516028, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=Lancet：严重急性肾损伤患者延迟肾脏替代治疗方案研究, objectType=article, longId=209572, objectId=ab582095e249, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab582095e249, replyNumber=0, likeNumber=64, createdTime=2022-02-24, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab582095e249, moduleTitle=Lancet：严重急性肾损伤患者延迟肾脏替代治疗方案研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab582095e249)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905145, encodeId=4ded19051450f, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=BMJ：全膝关节置换术后不良预后风险较高人群的后续康复治疗方案, objectType=article, longId=202213, objectId=ada720221337, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ada720221337, replyNumber=0, likeNumber=67, createdTime=2021-06-15, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ada720221337, moduleTitle=BMJ：全膝关节置换术后不良预后风险较高人群的后续康复治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ada720221337)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905165, encodeId=9e641905165e7, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=ASCO 2021: 摘要概览与展望 9 | 结直肠癌一线治疗方案, objectType=article, longId=211898, objectId=a7cd21189859, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7cd21189859, replyNumber=0, likeNumber=77, createdTime=2021-12-05, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7cd21189859, moduleTitle=ASCO 2021: 摘要概览与展望 9 | 结直肠癌一线治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7cd21189859)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905154, encodeId=0550190515445, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=JAMA neurology：重症肌无力患者不同激素治疗方案的效果比较, objectType=article, longId=207109, objectId=94f720e10924, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94f720e10924, replyNumber=0, likeNumber=0, createdTime=2021-04-09, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94f720e10924, moduleTitle=JAMA neurology：重症肌无力患者不同激素治疗方案的效果比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94f720e10924)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905178, encodeId=901919051e8d6, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=在非权威的医院工作，如何开展创新型较强的治疗方案？, objectType=article, longId=216015, objectId=e7d521601585, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7d521601585, replyNumber=0, likeNumber=85, createdTime=2021-11-15, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7d521601585, moduleTitle=在非权威的医院工作，如何开展创新型较强的治疗方案？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7d521601585)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905155, encodeId=55591905155d2, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=JAMA Netw Open：纳入多因素的AI辅助决策工具有助于为晚期膝骨关节炎患者制定更好的治疗方案, objectType=article, longId=207474, objectId=31e720e4743f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31e720e4743f, replyNumber=0, likeNumber=83, createdTime=2021-08-01, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31e720e4743f, moduleTitle=JAMA Netw Open：纳入多因素的AI辅助决策工具有助于为晚期膝骨关节炎患者制定更好的治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31e720e4743f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905148, encodeId=2863190514807, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=Circulation：秋水仙碱加入急性冠脉综合征的标准治疗方案会如何影响患者预后？, objectType=article, longId=203529, objectId=9e0b2035297c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e0b2035297c, replyNumber=0, likeNumber=0, createdTime=2021-01-15, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e0b2035297c, moduleTitle=Circulation：秋水仙碱加入急性冠脉综合征的标准治疗方案会如何影响患者预后？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e0b2035297c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905144, encodeId=d26e19051446d, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=真实世界研究表明，在晚期前列腺癌治疗方案中增加细胞疗法PROVENGE（sipuleucel-T）可使中位生存期延长14.5个月, objectType=article, longId=202159, objectId=6ecb20215929, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ecb20215929, replyNumber=0, likeNumber=62, createdTime=2020-12-13, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ecb20215929, moduleTitle=真实世界研究表明，在晚期前列腺癌治疗方案中增加细胞疗法PROVENGE（sipuleucel-T）可使中位生存期延长14.5个月, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ecb20215929)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905163, encodeId=c41719051636f, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=梅斯医学与西点药业就瑞香素胶囊多学科治疗方案学术推广达成战略合作！, objectType=article, longId=209938, objectId=a132209938d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a132209938d9, replyNumber=0, likeNumber=75, createdTime=2021-09-14, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a132209938d9, moduleTitle=梅斯医学与西点药业就瑞香素胶囊多学科治疗方案学术推广达成战略合作！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a132209938d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

治疗方案

2020-05-29

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

Lancet Oncol：CDKI联合氟维司群有望成为激素受体阳性、HER2阴性的晚期乳腺癌的标准治疗方案！

2022-09-06

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

J Clin Oncol：卡铂/依托泊苷方案+阿妥珠单抗作为广泛期小细胞肺癌一线治疗方案的延长随访预后结果（IMpower133试验）

2021-06-14

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

NEJM：利福喷丁-莫西沙星4个月治疗方案用于结核病的治疗

2021-08-16

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

骨髓瘤治疗新进展，全新作用机制药物Selinexor（ATG-010）三种治疗方案入选更新版NCCN®多发性骨髓瘤诊疗指南

2021-04-16

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

【瞩目】铂敏感复发性卵巢癌：卡铂-多柔比星-贝伐珠单抗或许是新的标准治疗方案

2021-11-12

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

J Clin Oncol：两种治疗方案对晚期霍奇金淋巴瘤年轻患者性腺功能的影响PK！

2022-01-08

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

Medicine：乌司他丁联合中药大黄可能是改善败血症的一种有前景的治疗方案

2021-05-21

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

JCO：两种辅助治疗方案用于I期HER2+乳腺癌患者的疗效对比

2022-02-25

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

Lancet Oncol：3期| 派姆单抗和化疗联用或单用作为晚期尿路上皮癌的一线治疗方案的疗效对比！

2022-03-18

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

Ann Hematol：ixazomib口服治疗方案有望成为NDMM患者的良好替代治疗选择

2021-08-29

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

HIV研究瞄准合并症风险，常规治疗方案难逃血脂问题

2021-12-06

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

Lancet：严重急性肾损伤患者延迟肾脏替代治疗方案研究

2022-02-24

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

BMJ：全膝关节置换术后不良预后风险较高人群的后续康复治疗方案

2021-06-15

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

ASCO 2021: 摘要概览与展望 9 | 结直肠癌一线治疗方案

2021-12-05

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

JAMA neurology：重症肌无力患者不同激素治疗方案的效果比较

2021-04-09

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

在非权威的医院工作，如何开展创新型较强的治疗方案？

2021-11-15

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

JAMA Netw Open：纳入多因素的AI辅助决策工具有助于为晚期膝骨关节炎患者制定更好的治疗方案

2021-08-01

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

Circulation：秋水仙碱加入急性冠脉综合征的标准治疗方案会如何影响患者预后？

2021-01-15

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

真实世界研究表明，在晚期前列腺癌治疗方案中增加细胞疗法PROVENGE（sipuleucel-T）可使中位生存期延长14.5个月

2020-12-13

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

梅斯医学与西点药业就瑞香素胶囊多学科治疗方案学术推广达成战略合作！

2021-09-14

科室
- - 订阅+
  - 更多科室
工具
服务